Cipla makes additional investment in German mRNA biotech

Ethris' has four potential drugs under development pipeline, of which one is for treating uncontrolled asthma and three other for primary ciliary dyskinesia - a rare yet chronic respiratory disease. During the COVID19 pandemic, mRNA vaccines gained importance due to the first regulatory approvals for SARS-CoV-2. mRNA-based medicines have a huge potential in several indications as infectious disease vaccines, therapeutic cancer vaccines, and protein replacement therapies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VNR0enH
via IFTTT